At the 2024 World Scientists Forum, Nobel Laureate in Physiology or Medicine Professor Carol Greider officially signed a cooperation agreement with ZhenCui (Jiangsu) Enzyme Technology Development Co., Ltd., announcing the establishment of a "Nobel Laureate Cooperation Workstation" and a joint effort with the Enzyme-Based Technology Innovation Institute (EBTII) to conduct research, aiming to achieve breakthrough progress in China's enzyme technology field. Dr. Zimmern Chow, founder of ZhenCui Technology, attended the signing ceremony and engaged in in-depth discussions with Professor Greider on the future direction of enzyme-based technology.
Professor Greider is a pioneer in telomere and telomerase research and received the Nobel Prize in 2009. Her research findings are highly complementary to ZhenCui Technology's core expertise in enzyme activation technology and the EACT process. The two parties will conduct in-depth collaboration focusing on areas such as enzyme-based multi-target cell activation.
The Enzyme-Based Technology Innovation Institute (EBTII), jointly established by ZhenCui Technology and Tianjin University of Science and Technology, reached its construction milestone with a topping-out ceremony on November 21, 2025. Professor Greider has been appointed as a visiting professor at ZhenCui Technology. "I look forward to achieving more milestones in enzyme-based technology together and contributing to human health," she said.
This partnership will accelerate ZhenCui Technology's scientific innovation and industrialization process, opening new pathways for the advancement of global enzyme-based technology.
